Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Cullinan Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 100 | 1 | 97 | −2 |
| Shares | 37.0M | 775 | 37.7M | +674.9K (+1.8%) |
| Value | $474.7M | $10.0K | $397.7M | −$76.9M (−16.2%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (12)
Institutions that held Cullinan Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Woodline Partners LP | 195,839 | $2.07M | 0.03% |
| Parkman Healthcare Partners LLC | 131,378 | $1.39M | 0.37% |
| Assenagon Asset Management S.A. | 83,010 | $876.0K | 0.00% |
| Ameriprise Financial Inc | 59,832 | $631.0K | 0.00% |
| Schonfeld Strategic Advisors LLC | 34,000 | $358.7K | 0.00% |
| SVB Financial Group | 27,032 | $285.2K | 0.78% |
| Tejara Capital Ltd | 23,600 | $249.0K | 0.14% |
| Prelude Capital Management, LLC | 11,544 | $121.8K | 0.01% |
| Fox Run Management, L.L.C. | 10,412 | $109.8K | 0.04% |
| Aquatic Capital Management LLC | 7,200 | $75.0K | 0.01% |
| Quadrant Capital Group LLC | 631 | $6.66K | 0.00% |
| Baker Avenue Asset Management, LP | 48 | $506 | 0.00% |
Sold out (14)
Institutions that held Cullinan Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Baupost Group LLCSuperinvestorBaupost Group | 429,646 | $5.51M |
| Marshall Wace, LLP | 40,576 | $520.0K |
| Alps Advisors Inc | 24,941 | $320.0K |
| Jump Financial, LLC | 21,700 | $278.0K |
| Susquehanna International Group, LLP | 19,775 | $254.0K |
| Two Sigma Advisers, LP | 15,000 | $192.0K |
| Cubist Systematic Strategies, LLC | 14,015 | $180.0K |
| Two Sigma Investments, LP | 13,100 | $168.0K |
| Leonteq Securities AG | 5,000 | $64.1K |
| Ensign Peak Advisors, Inc | 2,400 | $31.0K |
| Macquarie Group Ltd | 0 | $14.0K |
| Wells Fargo & Company | 71 | $1.00K |
| Signaturefd, LLC | 64 | $1.00K |
| Parallel Advisors, LLC | 10 | $0 |
Not filed for Q4 2022 yet (1)
Institutions that held Cullinan Therapeutics, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| FourThought Financial, LLC | 775 | $10.0K |